Tevogen Inc. Patent Applications Pending
11 applications still open at the USPTO, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.
- 2025-12-17: Application PCTUS2025060050; Invention SYSTEMS AND METHODS FOR PREDICTING T-CELL RECEPTOR ENGAGEMENT; Applicant TEVOGEN BIO INC.; Status RO PROCESSING COMPLETED-PLACED IN STORAGE.
- 2024-12-17: Application 63735193; Invention AI algorithms to predict T cell receptor engagement to specific HLA+ peptide complexes; Applicant Tevogen Bio Inc.; Status Provisional Application Expired.
- 2024-12-16: Application PCTUS2024060419; Invention SYSTEMS AND METHODS FOR PREDICTING IMMUNOLOGICALLY ACTIVE PEPTIDES WITH MACHINE LEARNING MODELS; Applicant TEVOGEN BIO INC.; Status RO PROCESSING COMPLETED-PLACED IN STORAGE.
- 2024-01-22: Application 18291142; Invention METHODS FOR DEVELOPING CD3+CD8+ CELLS AGAINST MULTIPLE VIRAL EPITOPES FOR TREATMENT OF VIRAL INFECTIONS INCLUDING VARIANTS EVOLVING TO ESCAPE PREVIOUS IMMUNITY; Applicant Tevogen Bio Inc.; Status Docketed New Case - Ready for Examination.
| Filed | Application | Invention | Applicant | Status | Published as | Inventor name | Inventor country | Examiner |
|---|---|---|---|---|---|---|---|---|
| 2025-12-17 | PCTUS2025060050 | SYSTEMS AND METHODS FOR PREDICTING T-CELL RECEPTOR ENGAGEMENT | TEVOGEN BIO INC. | RO PROCESSING COMPLETED-PLACED IN STORAGE | MITTUL MEHTA NEAL FLOMENBERG RYAN SAADI | United States United States United States | ||
| 2024-12-17 | 63735193 | AI algorithms to predict T cell receptor engagement to specific HLA+ peptide complexes | Tevogen Bio Inc. | Provisional Application Expired | Mittul MEHTA Neal FLOMENBERG Ryan SAADI | United States United States United States | ||
| 2024-12-16 | PCTUS2024060419 | SYSTEMS AND METHODS FOR PREDICTING IMMUNOLOGICALLY ACTIVE PEPTIDES WITH MACHINE LEARNING MODELS | TEVOGEN BIO INC. | RO PROCESSING COMPLETED-PLACED IN STORAGE | MITTUL MEHTA NEAL FLOMENBERG RYAN SAADI | United States United States United States | ||
| 2024-01-22 | 18291142 | METHODS FOR DEVELOPING CD3+CD8+ CELLS AGAINST MULTIPLE VIRAL EPITOPES FOR TREATMENT OF VIRAL INFECTIONS INCLUDING VARIANTS EVOLVING TO ESCAPE PREVIOUS IMMUNITY | Tevogen Bio Inc. | Docketed New Case - Ready for Examination | US20240358753A1 | Ryan SAADI | United States | ESPINOSA, CLAUDIA EDILMA |
| 2023-12-15 | 63611019 | AI algorithm to predict immunologically active HLA-peptide complexes | Tevogen Bio Inc. | Provisional Application Expired | Mittul MEHTA Neal FLOMENBERG Ryan SAADI | United States United States United States | ||
| 2022-07-29 | PCTUS2022038749 | METHODS FOR DEVEOPING CD3+CD8+ CELLS AGAINST MULTIPLE VIRAL EPITOPES FOR TREATMENT OF VIRAL INFECTIONS INCLUDING VARIANTS EVOLVING TO ESCAPE PREVIOUS IMMUNITY | TEVOGEN BIO, INC. | RO PROCESSING COMPLETED-PLACED IN STORAGE | RYAN SAADI | United States | ||
| 2021-12-09 | PCTUS2021062557 | VIRUS SPECIFIC T-CELLS AND METHODS OF TREATING AND PREVENTING VIRAL INFECTIONS | TEVOGEN BIO INC | RO PROCESSING COMPLETED-PLACED IN STORAGE | RYAN SAADI | United States | ||
| 2021-07-30 | 63227690 | Methods for Developing CD3+CD8+ Cells Against Multiple SARS-COV-2 Epitopes for Treatment of COVID-19 Including Variants Evolving to Escape Previous Immunity | Tevogen Bio Inc. | Provisional Application Expired | Ryan SAADI | United States | ||
| 2021-05-08 | 63186098 | VIRUS SPECIFIC T-CELLS AND METHODS OF TREATING AND PREVENTING VIRAL INFECTIONS | Tevogen Bio Inc. | Provisional Application Expired | Ryan SAADI | United States | ||
| 2020-12-09 | 63123109 | VIRUS SPECIFIC T-CELLS AND METHODS OF TREATING AND PREVENTING VIRAL INFECTIONS | Tevogen Bio Inc. | Provisional Application Expired | Ryan SAADI | United States | ||
| 19596562 | SYSTEMS AND METHODS FOR PREDICTING IMMUNOLOGICALLY ACTIVE PEPTIDES WITH MACHINE LEARNING MODELS | Tevogen Bio Inc. | Application Undergoing Preexam Processing | Mittul MEHTA Neal FLOMENBERG Ryan SAADI | United States United States United States |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B |